GARDEN GROVE, Calif., July 26, 2011 /PRNewswire/ -- HYCOR Biomedical, Inc., a leading manufacturer and marketer of in vitro diagnostic products, today announced that it has signed an agreement with Eurospital—a manufacturer of pharmaceutical products, medical-surgical and diagnostic devices—to license its tTG biomarker in all countries covered by the patent (excluding the US and Canada) for its ability to diagnose celiac disease. HYCOR today also announced that it has signed an agreement with AXIS-SHIELD—a developer of in vitro diagnostic tests—to license its anti-CCP biomarker for its ability to diagnose rheumatoid arthritis (RA). Customers will have access to these critical biomarkers from HYCOR in the coming weeks.
"We are pleased to offer HYCOR customers a tool to help clinicians diagnose these devastating, chronic diseases," said Dick Aderman, CEO, HYCOR. "We look forward to continuing to expand our diagnostic offerings, ensuring customers are able to meet the ever-changing needs of the healthcare professionals they serve."
Celiac disease is a condition that damages the lining of the small intestine and prevents it from absorbing nutrients properly, leading to malnutrition. The symptoms of celiac disease vary from one patient to the next, which poses challenges to healthcare professionals in the accurate diagnosis of the disease. If left untreated celiac disease can cause other complications, including autoimmune disease, anemia and hypoglycemia, and, in some instances, certain types of intestinal cancer.(i)
RA is a chronic autoimmune disease that leads to joint inflammation, as well as inflammation of the surrounding tissue. Early diagnosis of the disease, and early aggressive treatment, can delay joint destruction and prevent symptoms from worsening.(ii)
About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since it